About Polyoxidonium®

Polyoxidonium® has properties1 required at the stage of prevention and in the acute phase of viral infection.

Polyoxidonium pack
immunomodulating

Immunomodulating

Polyoxidonium® can activate cellular immunity and stimulate the production of its own interferons, increasing the body's resistance to viral infections1. The drug can help the body to combat the virus now and boost immunity for the future.

detoxifying

Detoxifying

Polyoxidonium® can absorb toxins and microparticles and remove them from the body1, reducing intoxication and improving the patient's condition from the first days of treatment.

anti-inflammatory

Anti-inflammatory

Polyoxidonium® can regulate the synthesis of inflammatory mediators. Depending on the baseline level, the drug can stimulate or suppress the synthesis of cytokines, regulating the balance of pro- and anti-inflammatory mediators1. Due to this property, Polyoxidonium® can alleviate the severity of the diseases2 and reduce clinical manifestations of inflammation3.

against bacterial complications

Against bacterial complications

Polyoxidonium® can activate the antibacterial protective properties of mucous membranes, preventing the occurrence of secondary bacterial infections and complications of viral diseases4.

preventive

Preventive

Polyoxidonium® is able to activate cellular and congenital immunity, which can help prevent infection and sickness during the cold season1.

Action of Polyoxidonium®

Polyoxidonium® can influence many immune response components1

The basis of the immunomodulating action of Polyoxidonium® is a direct effect on phagocytic cells and natural killers, as well as stimulation of antibody formation and synthesis of alpha and gamma interferons. The drug's detoxifying and antioxidant properties are determined by the structure and high-molecular nature of the drug1.
A characteristic feature of topically administered Polyoxidonium® is its ability to activate factors of body's early defense against infection: the drug can stimulate the bactericidal properties of neutrophils, macrophages, enhance their ability to absorb bacteria, increase the bactericidal properties of saliva and the secretion of the mucous membranes of the upper respiratory tract1.
Polyoxidonium® can delicately act upon the body: the drug can regulate the operation of the immune system without hyperstimulating it.

Polyoxidonium® and other immunotropic drugs

Polyoxidonium® is a chemically pure synthetic high-molecular immunomodulator of combined action. It is used for the treatment and prevention of acute diseases and exacerbations of chronic infectious diseases of bacterial, viral or fungal etiology.

vs

Interferons

Interferon drugs bring ready interferon active only against viruses into the body.

vs

Polyoxidonium®

Due to its ability to affect not only the synthesis of alpha and gamma interferons, but also other components of the immune system, Polyoxidonium® can combat not only viruses, but also bacteria and fungi1.

vs

Herbal products

Herbal ingredients of drugs can cause allergic reactions in people with allergic pathologies.

vs

Polyoxidonium®

Polyoxidonium® does not contain herbal ingredients, impurities and foreign DNA, so it can be used even by people with allergic pathologies. Besides, Polyoxidonium® has no significant side effects1.

vs

Bacterial lysates

Bacterial lysates carry an antigenic load.

vs

Polyoxidonium®

Unlike bacterial lysates, Polyoxidonium® does not carry any foreign antigenic load1, therefore the product can be administered even in children with allergies (aged 3 years and older).

Polyoxidonium® pharmaceutical forms

Tablets
Suppositories

Polyoxidonium® tablets 12 mg

  • For adults and children aged 3 years and older1.
  • Convenient sublingual administration, no need to take medicine with water. Take a tablet 20–30 minutes before meals1. Sublingual administration contributes to the activation of local immunity and generation of lysozyme (antibacterial enzyme) in saliva stimulating early body protection from infection.
  • Possible retreatment in 3–4 months1.
Polyoxidonium tablets pack
Scope of application of Polyoxidonium® tablets 12 mg
  1. Prevention/treatment of influenza and ARVI in adults and children
  2. Otorhinolaryngology
  3. Pulmonology
  4. Immunology/allergology

Dosage schedule

Children aged 3–10 years

  • For ARVI and influenza treatment
  • For ARVI and influenza prevention
  • 1/2 of a tablet
    2 times a day
    for 7 days
    1/2 of a tablet
    1 time/day
    for 7 days

Children aged over 10 years and adults

  • For ARVI and influenza treatment
  • For ARVI and influenza prevention
  • 1 tablet
    2 times a day
    for 7 days
    1 tablet
    1 time/day
    children aged over 10 years — 7 days
    adults — 10 days

Polyoxidonium® suppositories 6/12 mg

Suppositories 6 mg are for rectal administration in children aged over 6 years and adults.2

Suppositories 12 mg are for rectal/vaginal administration in adults.5

  • High bioavailability (not less than 70%), the maximum concentration in the blood stream is achieved in 1 hour after administration, systemic action.6
  • In case of vaginal administration, increases the level of slgA  — an important protective factor of reproductive tract.7
  • Possible retreatment in 3–4 months.6
Polyoxidonium pack
Scope of application of Polyoxidonium® suppositories 6 and 12 mg
  1. Gynecology
  2. Urology
  3. Prevention/treatment of influenza and ARVI
  4. Immunology/allergology

Dosage schedule

suppositories 12 mg

  • For the treatment of gynecological disorders
  • For the treatment of exacerbation of urological diseases (urethritis, pyelonephritis, cystitis, prostatitis)
  • For influenza and ARVI prevention
  • For the treatment of chronic infectious and inflammatory diseases in the acute stage
  • Adults
    1 suppositories 12 mg
    1 time / day, daily for 3 days, then every other day
    The treatment course consists of 10 suppositories
    1  suppositories 12 mg
    1 time / day daily
    The treatment course consists of 10 suppositories
    1  suppositories 12 mg
    1 time / day daily
    The treatment course consists of 10 suppositories
    1  suppositories 12 mg
    1 time / day daily for 3 days, then every other day
    The treatment course consists of 10 suppositories

Suppositories 6 mg

children aged 6 years and older6

  • For influenza and ARVI prevention
  • For the treatment of chronic infectious and inflammatory diseases in the acute stage
  • children aged 6 years and older
    1 suppositories 6 mg
    1 time / day
    The course consists of 10 suppositories
    1 suppositories 6 mg
    1 time / day daily for 3 days, then every other day
    The treatment course consists of 10 suppositories
In case of any drug-associated adverse events or any claims to the product quality, please contact NPO Petrovax Pharm, LLC:
Or use pharmacovigilance feedback page: http://petrovax.ru/medication/safety
  1. Patient information leaflet for Polyoxidonium® tablets 12 mg.
  2. Garaschenko, T.I., Karneeva, O.V., Tarasova, G.D., et al. (2020). Influence of local application of Polyoxidonium on symptoms and course of acute respiratory viral infection in children: results of multicenter double-blind placebo-controlled study. Consilium Medicum, 22(3), 80–86.
  3. Karaulov, A.V., Gorelov, A.V. (2019). The use of azoximer bromide for treatment of inflammatory infections of respiratory system in children: a meta-analysis of controlled clinical studies. Journal of Infectology, vol. 11, No. 4, 31–41.
  4. Morozova, S.V. (2010). The use of Polyoxidonium� immunocorrecting drug in acute infectious inflammatory pathology of ENT-organs. Russian Medical Journal, vol. 18, No. 24.
  5. Kharit, S.M., Galustyan, A.N. (2017). Azoximer bromide is a safe and effective drug for treatment of acute upper respiratory tract infections in children: an overview of the results of double-blind, placebo-controlled, randomized clinical trials of phase II and III. Pediatrics (Appendix to Consilium Medicum), 2.
  6. Patient information leaflet for Polyoxidonium® suppositories 6 and 12 mg.
  7. Letyaeva, O.I. Treatment of urogenital mixed infections in women of reproductive age: current state of problem. Gynecology, 6, 4–8.
Asc a question
If you have a non-standard question, please contact us. Attention! Referring to the site is not a substitute for consulting a doctor.
* Requirements fields
Asc a question
The question has been successfully sent, we will contact you shortly
Attention!

The information posted in this section is intended for medical and / or pharmaceutical professionals. Please confirm that you are a professional in the respective field.